Related by context. All words. (Click for frequent words.) 68 oral anticoagulant therapy 67 ribavirin therapy 67 Infusion Reactions Severe 67 postprocedure 66 Postoperative complications 66 antibiotic prophylaxis 65 PSA nadir 65 TMP SMX 65 atrioventricular block 65 recurrent ischemia 65 detectable HCV RNA 65 fibrinolytic therapy 65 biochemical relapse 65 EXJADE 65 TURBT 65 definite stent thrombosis 64 neutropenic sepsis 64 intravitreal injections 64 morphometric vertebral fractures 64 corticosteroid therapy 64 amoxicillin clavulanate 64 antimicrobial prophylaxis 64 palivizumab 64 ICD shocks 64 elevated transaminases 64 neutropenic patients 64 severe neutropenia 64 acute STEMI 64 systemic corticosteroid 64 virologic failure 64 elevated ALT 64 reinfarction 64 NATRECOR ® 64 receiving XGEVA 64 evaluable subjects 64 transaminase elevations 63 maximal doses 63 placebo dexamethasone 63 HBeAg seroconversion 63 ALT flares 63 dopaminergic therapy 63 severe hypersensitivity reactions 63 FluCAM arm 63 moderate renal impairment 63 severe exacerbations 63 virological response 63 ATACAND 63 intravenous bisphosphonates 63 8mg/kg 63 postoperative chemotherapy 63 serum aminotransferase levels 63 HBeAg negative 63 undetectable HBV DNA 63 PASI scores 63 total thyroidectomy 63 neutropenia dehydration dyspnea 63 weekly subcutaneous injections 63 NSAID therapy 63 hypophosphatemia 63 perioperatively 63 PegIFN RBV 63 tirofiban 63 undergone splenectomy 62 hypomagnesemia 62 VTE prophylaxis 62 candidemia 62 methotrexate monotherapy 62 haematologic 62 invasive candidiasis 62 leucopenia 62 DES implantation 62 chemoradiation therapy 62 bolus dose 62 oral corticosteroids 62 decompensated liver disease 62 visceral metastases 62 MRSA colonization 62 CCyR 62 thromboembolic complications 62 complete cytogenetic response 62 recurrent VTE 62 rFVIIa 62 angiographic outcomes 62 RBC transfusions 62 postoperative complication 62 recurrent glioblastoma multiforme 62 genotypic resistance 62 IOP lowering 62 anagrelide 62 electrical cardioversion 62 ribavirin RBV 62 mg kg dose 62 symptomatic VTE 62 intravenous bolus 62 chlorambucil 62 β blockers 62 achieved ACR# 62 Ribavirin causes 62 reperfusion therapy 62 antithrombotic therapy 62 severe renal impairment 62 hemodynamically unstable 62 vaginal hysterectomy 62 chronic GVHD 62 neutropenic fever 62 K ras mutations 62 operable breast cancer 62 β blocker 62 IV bisphosphonates 62 ß blockers 62 nephrotoxicity 62 alteplase 62 Adjuvant chemotherapy 62 chest radiographs 62 splenectomized patients 62 MAGE A3 ASCI 62 weekly intravenous infusions 62 arteriography 62 febrile illness 62 CMV infection 62 argatroban 62 elective PCI 62 thromboprophylaxis 62 aromatase inhibitor therapy 62 virologic breakthrough 62 Y BOCS 62 rebleeding 62 #mg BID [001] 62 reduce serum phosphate 62 relapsed MM 62 pentoxifylline 62 anemia neutropenia 62 biologic DMARD 62 paroxysmal AF 62 abdominal hysterectomy 62 upper gastrointestinal bleeding 61 RSV hospitalizations 61 octreotide LAR 61 reintubation 61 curative resection 61 postoperative hemorrhage 61 solifenacin 61 VP# [004] 61 thromboembolic events 61 Kaplan Meier analysis 61 TNF antagonist 61 prolonged QT interval 61 recurrent genital herpes 61 GnRH agonists 61 HBV infections 61 Clinically significant 61 FOLFIRI alone 61 dose escalation phase 61 budesonide pMDI 61 clot busting therapy 61 neutropaenia 61 pancreatic resection 61 reoperations 61 aflibercept VEGF Trap 61 colectomy 61 pegylated alpha interferon 61 Hypertensive adverse reactions 61 ARB telmisartan 61 thrombolytic therapy 61 postoperative morbidity 61 CIN3 61 lipid lowering therapy 61 primary percutaneous coronary 61 imipenem 61 Hypotension 61 abacavir lamivudine 61 ICD implantation 61 concomitant medication 61 hematologic toxicity 61 elevated serum creatinine 61 Subgroup analyzes 61 virological failure 61 cisplatin chemotherapy 61 Stent thrombosis 61 APTIVUS r 61 CHOP chemotherapy 61 anterior uveitis 61 CR CRu 61 angioneurotic edema 61 deep venous thromboses 61 refractory ischemia 61 immune thrombocytopenic purpura ITP 61 postoperative infection 61 hepatorenal syndrome 61 SLNB 61 adefovir treated 61 certolizumab 61 hypercalcemia 61 lymphocytosis 61 postexposure prophylaxis 61 methotrexate therapy 61 mcg kg REBETOL 61 invasive aspergillosis 61 sUA 61 antiplatelet medications 61 thrombophlebitis 61 eculizumab therapy 61 steroid dexamethasone 61 hepatic metastases 61 EDARBI 61 drug eluting stent implantation 61 thrombotic complications 61 cytopenias 61 platelet transfusion 61 fibrinolysis 61 syncope fainting 61 ABRAXANE therapy 61 IFN alfa 61 chronic idiopathic thrombocytopenic purpura 60 trimethoprim sulfamethoxazole 60 interferon ribavirin 60 colorectal liver metastases 60 mucocutaneous reactions 60 hepatectomy 60 receiving highly emetogenic 60 NSTEMI 60 cranial irradiation 60 glycoprotein IIb IIIa inhibitor 60 tipranavir ritonavir 60 HBV DNA levels 60 generalized edema 60 receiving VICTRELIS 60 adjuvant radiotherapy 60 adjuvant radiation 60 corticosteroids immunoglobulins 60 ERBITUX infusion 60 erythema nodosum 60 doxorubicin docetaxel 60 hemoptysis 60 herpes zoster vaccine 60 cerebral angiography 60 rt PA 60 anticoagulation therapy 60 mCRC patients 60 recurrent UTI 60 androgen deprivation 60 remission induction 60 MCyR 60 recurrent DVT 60 interstitial pneumonia 60 Pegasys plus Copegus 60 lenalidomide Revlimid R 60 interferon alfa 2b 60 CDI recurrence 60 COPD exacerbation 60 riociguat 60 â ‰ ¥ 60 oral methylnaltrexone 60 inhospital 60 postoperative mortality 60 conjunctival hyperemia 60 virologic response 60 PRADAXA 60 corticosteroid dose 60 superficial basal cell carcinoma 60 salmeterol fluticasone 60 aspartate aminotransferase AST 60 postintervention 60 CsA 60 node metastases 60 BARACLUDE ® 60 postexposure 60 antiretroviral naive 60 systemic hypotension 60 desvenlafaxine succinate 60 haematuria 60 tumor lysis syndrome 60 metastatic malignant melanoma 60 Doxil ® 60 non valvular atrial 60 sustained virologic response 60 P = .# 60 adrenal suppression 60 AST ALT 60 levodopa therapy 60 immunosuppression therapy 60 receiving VELCADE 60 febrile neutropenia 60 renal insufficiency 60 symptomatic intracranial 60 rosuvastatin #mg 60 clodronate 60 serum phosphorous 60 bacteremia 60 glucocorticoid therapy 60 endophthalmitis 60 prior chemotherapy regimens 60 HBeAg positive patients 60 anthracycline taxane 60 clomipramine 60 beta blocker therapy 60 chronic HCV 60 nodal metastases 60 cerebrovascular events 60 AMEVIVE 60 chemoradiotherapy 60 Zometa hazard 60 vesicoureteral reflux 60 PSADT 60 liver biopsies 60 seroprotection 60 angiographic restenosis 60 trastuzumab Herceptin ® 60 intravenous tPA 60 NSTE ACS 60 hypokalemia 60 dose Iluvien 60 low dose Iluvien 60 pamidronate 60 PLX STROKE targeting 60 glomerular filtration 60 decompensated heart failure 60 severe hypoglycemic 60 antiretroviral naïve 60 adalimumab Humira 60 posttreatment 60 FOLFOX4 60 postoperative infections 60 thrombocytopenic 60 aldosterone antagonist 60 saline placebo 60 recurrent malignant glioma 60 metastatic malignant 60 bacteriuria 60 XIENCE V PROMUS Stent 60 calculated creatinine clearance 60 imatinib therapy 60 peginterferon 60 HbA 1c levels 60 prospectively stratified 60 receiving immunosuppressive therapy 60 leukopenia 60 neovascular 60 symptomatic hyponatremia 60 ritonavir boosted protease inhibitor 60 aminotransferases 60 plasma cortisol 60 mild renal insufficiency 60 % CI #.#-#.# [007] 60 REYATAZ r arm 60 DLTs 60 divalproex sodium 60 5-FU/LV 60 ipsilateral stroke 60 bacteraemia 60 del 5q MDS 60 ARCALYST ® 60 4mg/kg 60 acid suppressive therapy 60 #mg QD [002] 60 achieved sustained virologic 59 lenalidomide dexamethasone 59 oral diclofenac 59 anthracycline therapy 59 plus dexamethasone 59 arterial thromboembolic events 59 paraprotein 59 COPD exacerbations 59 CP CPPS 59 esophageal candidiasis 59 dalteparin 59 NMIBC 59 macrolide antibiotic 59 #mg QD [001] 59 zolmitriptan 59 mcg BID 59 serum cortisol 59 #.#ng/ml 59 colorectal adenoma 59 Lactic acidosis 59 alanine aminotransferase ALT 59 proctitis 59 HIV coinfected 59 QTc prolongation 59 proliferative retinopathy 59 sustained ventricular tachycardia 59 non metastatic osteosarcoma 59 orchitis 59 antiarrhythmic drugs 59 DVT prophylaxis 59 advanced adenoma 59 chest radiography 59 oral rivaroxaban 59 pharmacologic stress 59 alfa 2a 59 cytotoxic therapy 59 FOLFOX4 alone 59 postoperative atrial fibrillation 59 NAbs 59 intravitreal injection 59 FOLPI regimen 59 MACCE 59 bisphosphonate therapy 59 renal dysfunction 59 renal allograft 59 FROVA 59 relapsed SCLC 59 nitrofurantoin 59 mg/m2 dose 59 elevated bilirubin 59 STELARA ™ 59 posttransplant 59 Subgroup analysis 59 paclitaxel Taxol R 59 INVEGA ® 59 AA Amyloidosis 59 induction regimen 59 unstable angina pectoris 59 moderately emetogenic 59 thromboembolic 59 ACTEMRA TM 59 defibrillator implant 59 detrusor overactivity 59 included exfoliative dermatitis 59 asymptomatic hyperuricemia 59 Postoperatively 59 debulking surgery 59 bronchoalveolar lavage BAL 59 Helicobacter pylori eradication 59 gross hematuria 59 Lupuzor ™ 59 TEAEs 59 malignant polyps 59 atorvastatin #mg 59 Erythropoietic therapies may 59 ASCUS 59 acute aortic dissection 59 hemodynamically stable 59 asthma exacerbation 59 nephrotoxic drugs 59 Raptiva r 59 docetaxel chemotherapy 59 radioiodine therapy 59 bovine thrombin 59 recurrent myocardial infarction 59 CANCIDAS 59 urate lowering therapy 59 mitoxantrone plus 59 dysmenorrhoea 59 lichen planus 59 mg QD 59 unresectable tumors 59 Peginterferon alfa 2b 59 inotropic 59 VCUG 59 nicardipine 59 severe oral mucositis 59 PEGINTRON TM 59 revascularization procedure 59 CR nPR 59 eplerenone 59 adenoidectomy 59 NATRECOR R 59 Oral corticosteroids 59 glycated hemoglobin levels 59 cystoscopic 59 anthracycline containing 59 eosinophilic pneumonia 59 SCIg 59 headache abdominal pain 59 dose titration 59 salmeterol HFA MDI 59 CLL SLL 59 postoperative AF 59 locoregional recurrence 59 Zevalin consolidation 59 CIMZIA ™ 59 postoperative pulmonary 59 HIV HCV coinfected 59 #Gy 59 atherothrombotic events 59 ALT normalization 59 Lucentis injections 59 intravesical therapy 59 DMARD therapy 59 acute gout flares 59 neoadjuvant radiation 59 systolic dysfunction 59 systemic corticosteroids 59 VELCADE melphalan 59 basal bolus regimen 59 histologically confirmed 59 OAB symptoms 59 Non inferiority 59 pyrexia mucositis sepsis febrile 59 empiric therapy 59 Pemetrexed 59 ticlopidine 59 colonoscopic 59 acid suppressive medication 59 hemodynamically significant 59 intradermal injections 59 MULTAQ 59 fragility fracture 59 CIN3 + 59 infliximab monotherapy 59 prednisone prednisolone plus 59 #mg/day [001] 59 clopidogrel pretreatment 59 revascularizations 59 incidence ≥ 59 calcineurin inhibitor 59 chronic hemodialysis 59 anti HBs 59 liver resection 59 LYSTEDA 59 glycoprotein IIb IIIa inhibitors 59 R0 resection 59 endometrial biopsy 59 vaccinees 59 mg ustekinumab 59 SSTIs 59 intracranial hemorrhage ICH 59 vincristine doxorubicin 59 TORISEL 59 C difficile infection 59 periprocedural 59 briakinumab 59 C. difficile diarrhea 59 paracentesis 59 PPSV# 59 recurrent herpes labialis 59 serum urate 59 Tysabri infusions 59 thrombotic events 59 ALND 59 NNRTI resistance 59 BENICAR HCT 59 pCR 59 pneumonectomy 59 fluticasone salmeterol 59 GnRH agonist 59 myelodysplastic myeloproliferative diseases 59 symptomatic hypotension 59 tachyarrhythmias 58 NPH insulin 58 concomitant medications 58 RLAI 58 renal scarring 58 intrathecal chemotherapy 58 unstable angina UA 58 FXIII 58 heavily pretreated 58 intravenous vancomycin 58 nadolol 58 chlamydial 58 FRAGMIN 58 anthracyclines taxanes 58 undetectable hepatitis C 58 hyperacute 58 hyperphenylalaninemia HPA due 58 mEq L 58 VT VF 58 protease inhibitor PI 58 AGHD 58 herpes zoster shingles 58 recurrent atrial fibrillation 58 ZYVOX 58 eosinophilic asthma 58 DAPT 58 recurrent metastatic 58 Febrile neutropenia 58 glucocorticoid induced osteoporosis 58 pegylated interferon alfa 58 hsCRP levels 58 receiving INTRON 58 serum magnesium 58 pulmonary resection 58 ARCOXIA 58 underwent resection 58 null responder HCV 58 subtrochanteric 58 DOXIL 58 bezafibrate 58 chest radiograph 58 Viral load 58 HBeAg + 58 flutamide 58 paclitaxel eluting stents 58 antiemetic therapy 58 peginterferon alfa 58 response CCyR 58 immunocompetent patients 58 pulmonary exacerbation 58 multiple concomitant medications 58 postoperative bleeding 58 vitreous haze 58 parathyroidectomy 58 recurrent GBM 58 severe dermatologic toxicities 58 fibrinolytic 58 tipranavir r 58 monoinfected patients 58 severe hypoglycemia 58 plasma HCV RNA 58 cardiac tamponade 58 HCV antibody 58 rtPA 58 triamcinolone 58 liver decompensation 58 hematological toxicity 58 cytogenetic response 58 infusional 58 Intravenous immunoglobulin 58 tolterodine ER 58 tumor resection 58 abdominal ultrasounds 58 Toxicities 58 ibandronate 58 serum sodium levels 58 elevated LDH 58 PREZISTA r 58 ALT elevations 58 TNF blocker therapy 58 MS relapses 58 abnormal Pap smear 58 invasive fungal infection 58 HSCT 58 samalizumab 58 PRADAXA #mg 58 timepoint 58 mcg doses 58 hypocalcemia 58 hemorrhagic cystitis 58 ICD therapy 58 myalgia arthralgia 58 #mg/day [002] 58 VIIBRYD 58 nonmetastatic prostate cancer 58 seroconversion 58 specific antigen PSA 58 pathologic fractures 58 anaphylactoid reactions 58 overnight polysomnography 58 droperidol 58 tacrolimus ointment 58 adrenalectomy 58 asymptomatic PAD 58 ximelagatran 58 prodromal symptoms 58 antibody titer 58 hyperbilirubinemia 58 nephrotoxic 58 surgical prophylaxis 58 primary immunodeficiency PI 58 intensive statin therapy 58 seroconverted 58 plus methotrexate 58 LNG IUS 58 hereditary deficiency 58 ARIXTRA 58 Fanconi syndrome 58 torsade de pointes 58 thalidomide dexamethasone 58 PNH patients 58 chlamydial infection 58 nonvertebral fracture 58 Infusion reactions 58 perioperative morbidity 58 ZOMETA 58 insulin secretagogue 58 adenoma recurrence 58 oral antidiabetes 58 MYCAMINE 58 varicella infection 58 mucosal lesions 58 adnexal mass 58 daily subcutaneous injections 58 pretest probability 58 #mg/m# [002] 58 Heavy menstrual bleeding 58 canakinumab 58 ALT elevation 58 achieved sustained virological 58 severe hepatic dysfunction 58 events TEAEs 58 CIMZIA TM certolizumab pegol 58 genital ulcers 58 sustained virological response 58 CMV disease 58 binary restenosis 58 activator tPA 58 inhaled bronchodilators 58 GH deficiency 58 antiangiogenic therapy 58 non splenectomized 58 myopathy rhabdomyolysis 58 achieved PASI 58 mcg Albuferon 58 decompressive surgery 58 insulin detemir 58 syncopal episodes 58 asymptomatic carotid stenosis 58 conjugated equine estrogen 58 hematopoietic cancers 58 fetal malformations 58 ritonavir boosted 58 pretreatment baseline 58 acute GvHD 58 mycophenolate mofetil MMF 58 ertapenem 58 serum phosphate 58 CLARITY study 58 liver metastasis 58 carotid revascularization 58 cefazolin 58 autoantibody positive 58 onset atrial fibrillation 58 suppressive therapy 58 clinically meaningful improvement 58 transfusion transmitted 58 nosocomial pneumonia NP 58 microbiologically evaluable 58 symptom exacerbation 58 vitreous hemorrhage 58 subarachnoid hemorrhage SAH 58 FASLODEX 58 cervical lymph nodes 58 warfarin therapy 58 adjuvant tamoxifen 58 mcg albinterferon alfa 2b 58 unruptured aneurysm 58 goserelin 58 QTcF 58 spontaneous bacterial peritonitis 58 liposomal amphotericin B 58 blood dyscrasias 58 penicillin allergy 58 seropositive patients 58 delayed gastric emptying 58 serum HBV DNA 58 HBsAg 58 remission CR 58 related hematological toxicity 58 EDSS scores 58 repeat paracentesis 58 S. aureus sepsis 58 immune thrombocytopenic purpura 58 oral vancomycin 58 elevated troponin 58 Surgical resection 58 #ng/ml 58 neutrophil count 58 atazanavir ritonavir 58 achieve sustained virologic 58 intravenous heparin 58 cystoid macular edema 58 intravascular hemolysis 58 PAOD 58 #mg dose [002] 58 PREZISTA ritonavir 58 achieved CCyR 58 DOXIL ® 58 nonoperative treatment 58 alemtuzumab treated 58 hematologic abnormalities 58 IELT 58 acute myocarditis 58 unresectable HCC 58 biliary obstruction 58 stage IIIb IV 58 ICD implants 58 surgical debulking 58 coronary revascularization 58 hepatic toxicity 58 cidofovir 58 APTIVUS ritonavir 58 pheochromocytoma 58 abnormal Pap smears 58 cGy 58 orchiectomy 58 LMWH 58 mitomycin C 58 mycophenolate mofetil 58 overt hepatic encephalopathy 58 abnormal pap smear 58 Lamictal XR 58 dual antiplatelet therapy 58 highly emetogenic 58 wound dehiscence 58 undetectable HCV RNA 58 biochemical recurrence 58 NIHSS score 58 pyrazinamide 58 oral prednisone 58 HeFH 58 potentially hepatotoxic 58 % CI #.#-#.# [003] 57 transaminases 57 HBsAg positive 57 azoospermia 57 oxycodone CR 57 laparoscopically assisted 57 SVR# 57 choroidal neovascularization CNV 57 asymptomatic AF 57 syncopal 57 BYSTOLIC 57 affective psychosis 57 noncardiovascular mortality 57 unresectable recurrent 57 Mg Uk 57 circulating EPCs 57 Perforomist Inhalation Solution 57 pyridostigmine 57 extubation 57 Tumor shrinkage 57 posaconazole 57 gout flares 57 coronary arteriography 57 HALAVEN 57 Liver transplantation 57 pouchitis 57 delayed CINV 57 KRAS mutant tumors 57 dose proportionality 57 tumor progression TTP 57 endometrial hyperplasia 57 ug dose 57 oral anticoagulation 57 prior nephrectomy 57 metastatic RCC 57 vitreous floaters 57 serum estradiol 57 IXEMPRA 57 dosage regimens 57 RRMS patients 57 overlapping stents 57 ventricular tachycardia VT 57 microalbumin test 57 Myelosuppression 57 Hypokalemia 57 bacterial prostatitis 57 renal toxicity 57 serum HCV RNA 57 telaprevir dosed 57 KETEK 57 precancerous condition 57 empiric treatment 57 rituximab monotherapy 57 BEXXAR Therapeutic Regimen 57 creatine kinase MB 57 symptomatic pulmonary embolism 57 radiotherapy RT 57 renal cysts 57 intravenous diuretics 57 postoperative nausea 57 opioid analgesia 57 somatostatin analog 57 Elitek 57 TYGACIL 57 placebo p = 57 pathologic fracture 57 bolus injection 57 urinary N telopeptide 57 alefacept 57 unfractionated heparin 57 vasospasm 57 irbesartan 57 via intradermal injections 57 multivessel disease 57 HAV infection 57 preoperative chemotherapy 57 chronic eosinophilic leukemia 57 cytoreduction 57 percutaneous drainage 57 mg eq 57 squamous cell lung cancer 57 induce orthostatic hypotension 57 pathologic diagnosis 57 aspirin clopidogrel 57 im peramivir 57 gemifloxacin 57 mediastinitis 57 Multivariate analyzes 57 coagulation parameters 57 anakinra 57 KRAS mutations occur 57 idiopathic thrombocytopenic purpura 57 glycated hemoglobin HbA1c 57 secondary efficacy endpoint 57 hyperammonemia 57 oral FTY# 57 mg q#h 57 hepatic insufficiency 57 cilostazol 57 susceptible isolates 57 malignancy HCM 57 infective endocarditis 57 standard chemotherapy regimen 57 dose cohort 57 URTI 57 lumbar spine BMD 57 chronic periodontitis 57 colon resection 57 intracerebral hemorrhage 57 neurologic symptoms 57 malignant neoplasms 57 PCNSL 57 asthma exacerbations 57 UPPP 57 transaminase levels 57 gonococcal infections 57 empyema 57 EGFR mutation positive 57 viral kinetics 57 nonresponders 57 hepatitis C genotype 57 HBeAg negative patients 57 etomidate 57 lamivudine refractory patients 57 baseline HbA1c 57 duplex ultrasonography 57 colorectal cancer liver metastases 57 leiomyomas 57 acute myocardial 57 anticoagulant therapy 57 adjunctive placebo 57 complete cytogenetic 57 pulmonary dysfunction 57 poor metabolizers 57 partial remissions 57 adverse cytogenetics 57 normothermic 57 underwent coronary angiography 57 de novo kidney transplant 57 mg BID 57 antibody titers 57 resolves spontaneously 57 recurrent urinary tract infection 57 underwent surgical resection 57 tapentadol ER 57 tegaserod 57 Noxafil 57 neurologic deficits 57 scintigraphic 57 hypoglycemic episodes 57 carotid artery blockage 57 active ankylosing spondylitis 57 venous thromboembolic disease 57 precancerous cervical 57 Q#IR 57 rhGH 57 docetaxel Taxotere ® 57 preintervention 57 Pharmacokinetics PK 57 antiepileptic medications 57 bullous 57 cytomegalovirus infection 57 DMARD 57 chemotherapy docetaxel 57 mcg dose 57 NEUPOGEN 57 QTc intervals 57 fluvastatin 57 receiving APTIVUS r 57 mycophenolate 57 sacral neuromodulation 57 enzyme elevations 57 icatibant 57 pT3 57 #mg/m# [001] 57 rimonabant #mg 57 intracerebral haemorrhage 57 latent tuberculosis infection 57 nebulization 57 5-fluorouracil/leucovorin 57 deep vein thromboses 57 LEXIVA r 57 SGPT 57 basiliximab 57 refractory CLL 57 revascularization procedures 57 Kinoid 57 idraparinux 57 neurologic complications 57 plus gemcitabine 57 peginterferon alfa 2b 57 AVODART 57 nucleoside naive 57 antiviral therapy 57 Lucentis monotherapy 57 treatment naive genotype 57 titration phase 57 neurologic progression 57 external beam radiotherapy 57 histologic subtype 57 serum potassium 57 NNT = 57 Traficet EN 57 lamivudine monotherapy 57 oxycodone IR 57 cefotaxime 57 upper endoscopy